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Inflammatory conditions such as Rheumatoid Arthritis (RA) are characterised by 
impaired bone health, with bone loss occurring both systemically and locally 
(erosions). Other conditions, such as Diffuse Idiopatic Skeletal Hyperostosis 
(DISH) are not usually associated with significant systemic inflammation but 
nonetheless can show signs of impaired bone health, in the form of osteoporosis 
and bone ectopic neoformation. The Wnt/B-catenin pathway is the master regulator 
of osteogenesis, and its role has been extensively investigated in the last years. The 
objective of the presen thesis is to investigate the role of the main Wnt pathway 
modulators (Dkk-1 and sclerostin) in inflammatory conditions such as RA and 
polymyalgia rheumatica and the effect of different treatment on their serum levels. 
Furthermore, the Wnt pathway dysregulation in a non-inflammatory conditions 
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During my PhD program in Clinical and Experimental Biomedical Science, 
attended at the Rheumatology Unit at the University of Verona, I further 
investigated the involvement of the Wnt pathway in the development of bone 
damage in chronic rheumatic conditions characterised by a high degree of chronic 
inflammation, such as Rheumatoid Arthritis (RA) and Polymyalgia Rheumatica 
(PMR) and conditions not associated with it, such as Diffuse Idiopathic Skeletal 
Hyperostosis (DISH). 
In this final thesis mi intent is to examine some of the most interesting findings 
documented in my research, in patients affected by these conditions and receiving 
treatment with different drugs (i.e. different monoclonal antibodies, corticosteroids) 
 
BACKGROUND 
Chronic Arthritides and bone involvement: from Rheumatoid to Psoriatic 
Arthritis and Ankylosing Spondylitis 
Rheumatoid arthritis (RA) is an inflammatory autoimmune arthropathy 
characterized by progressive chronic articular destruction. Bone damage occurs at 
joint sites with the development of erosions, and this is often regarded as the 
prevalent bone problem in RA (1). The pathophysiology of these skeletal 
involvements is still poorly understood. Bone is not static and its cells are targeted 
by many signalling pathways. Cytokines as Tumor Necrosis Factor-α (TNFA) and 
Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) and Antibodies to 
Citrullinated Protein Antigens (ACPAs) could, for example, act directly on 
osteoclasts (2,3). Articular bone erosion represents localized bone loss (osteolysis), 
initially involving cortical bone, and destruction of the natural barrier between the 
extraskeletal tissue and the intertrabecular spaces of the bone marrow cavity. 
Osteolysis results from an imbalance in which bone resorption by osteoclasts is 
favoured over bone formation by osteoblasts. Understanding the mechanisms that 
define the formation of bone erosions requires insight into the biology of bone 
homeostasis and the molecular regulation of the differentiation and function of 
osteoclasts and osteoblasts (1). Initially described more than 100 years ago (1), 
articular bone erosions have now become a central element in the diagnosis, 
treatment and monitoring of RA. Moreover, these lesions are an expected 
consequence of seropositive RA if the disease is not treated in a timely and effective 
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fashion. Erosions reflect the clinical consequence of the tight interaction between 
immune activation and skeletal modelling and remodelling. Indeed, research into 
the interface between the immune system and bone has now led to a new field, 
termed osteoimmunology (1). 
Psoriatic arthritis (PsA) is an inflammatory disease involving the skin, the entheses, 
and the joints (4). Hand joint involvement is a typical feature of PsA and is 
characterized by synovial inflammation, which leads to swelling, pain, and stiffness 
of the affected joints. Clinical symptoms of PsA resemble, in part, those observed 
in RA; however, the anatomic changes observed in PsA are substantially different 
from those observed in RA. Thus, PsA is characterized by sites of new bone 
formation along the periarticular bone, which are not present in RA (5). The 
pathogenesis of these lesions is incompletely understood but may reflect the 
association of PsA with inflammation of structures representing the insertion sites 
of the tendons (enthesitis). Fibrocartilage, a specialized tissue typical of these sites, 
is responsible for the transduction of mechanical strain from tendons to bone (6). It 
has been suggested that inflammation of the entheses triggers new bone formation 
along these structures, which then appears radiographically as entheseophytes. 
Ankylosing spondylitis (AS) is a chronic rheumatic disease characterized by 
inflammation and extensive remodelling of spine and joints. In contrast to RA and 
somewhat similarly to PsA, destructive changes are limited in AS, but extensive 
new bone formation results in the development of spinal syndesmophytes and extra-
articular enthesophytes, leading to joint or spine ankylosis (7). Parallel to the 
osteoproliferation, patients with AS also have an increased loss of bone, resulting 
in an elevated risk for vertebral fractures (8). 
 
The WNT pathway and bone remodeling 
The characterization of the canonical WNT pathway in the regulation of bone 
modeling and remodeling provided important insights in our understanding of the 
pathophysiology of bone involvement in chronic arthritis (9–11). The 
understanding of the mechanisms responsible of osteclastogenesis dates back to the 
’90, when several studies analysed the role of the receptor activator of nuclear factor 
kappa-B ligand (RANKL)/osteoprotegerin (OPG) in the regulation of osteoclasts 
(OCs) maturation. Under the control of different factors, involving hormones, 
growth factors and some cytokines, the osteoblast (OB) secretes a specific mediator 
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belonging to the Tumour Necrosis Factor family called RANKL. This molecule 
interacts with its specific receptor RANK, which is present on both the 
mononucleated haematopoietic precursors of the monocyte-macrophage line and 
on the mature OC. The interaction between RANKL and RANK promotes the 
differentiation of the mononucleated precursors in multinucleated precursors and, 
finally, in mature OCs (12). In vivo, there is a physiological control mechanism 
represented by a “decoy” receptor called OPG, also of OB origin, capable of 
binding RANKL and thus blocking the interaction with RANK present on the 
precursors of the OC. This way, it prevents not only their differentiation, but also 
inhibits the activation of mature OC and reduces their survival (12). 
The WNT pathway is a complex transduction pathway which transmits the signal 
from the receptors localized on the cell membrane, to the cytoplasm and finally to 
the nucleus, there regulating the genic transcription. WNT comprehends a family 
of proteins mediating several biologic processes such as embryogenesis, 
organogenesis, tissue regeneration and tumour-genesis, through both a paracrine 
and autocrine action (13–16). 
We can divide two main signalling pathways: the canonical and the non-canonical 
pathway. With the term non-canonical pathway we summarize different signals not 
involving β-catenin but different kinases such as Mitogen Activated Protein and 
kinase protein calcium/calmodulin dependent (17). Those pathways regulate 
proliferation, differentiation and cellular migration (18) with effects on bone tissue 
that are still not deeply understood. However, it is conceivable that they may play 
a role in the skeletal physiology of adults too. 
The canonical signalling of WNT/β-catenin is the most understood pathway and, 
probably, the most relevant. It determines the stabilization of β-catenin already 
present in the cytoplasm and its translocation in the nucleus where it regulates genic 
expression, thus influencing several and bone formation and several other features 
such as (19–23): 
• Stem cells renewal 
• Differentiation of the OB from the staminal mesenchymal precursors and 
inhibition of adipogenesis and chondrogenesis (24,25) 
• Proliferation, survival, maturation and activity of the OBs 
• Inhibition of osteoclastogenesis 
• Regulation of the coupling processes between OBs and OCs 
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The WNT canonical pathway contributes to the osteogenesis and bone formation. 
In addition, the WNT/β-catenin can inhibit osteclastoogenesis and bone resorption 
by promoting the expression of OPG by OBs unbalancing OPG/RANKL ratio 
(26,27). Thus, the WNT canonical pathway acts on the bone metabolism with a dual 
mechanism: the stimulus on bone formation and inhibition on bone resorption. 
WNT regulation is determined by the production of intra- and extracellular 
inhibitors (15), acting in very different manners  (28). Some WNT Inhibitory 
Factors (WIFs) directly bind to WNT proteins or their receptors blocking both the 
two pathways. On the contrary, Dickkopf-related protein-1 (Dkk-1) and sclerostin 
interfere with Low density lipoprotein receptor-related proteins (LRPs) co-
receptors and thus inhibiting only WNT canonical pathway (29–31). 
Based on these premises, it is evident that the inhibition of the development, 
functionality and survival of OCs through the inhibition of RANKL and the 
influence on RANK/OPG balance can represent an effective strategy to modify the 
physiology of bone resorption, either systemic or local, and to oppose the 
fundamental physiopathological feature of bone loss.  
 
The WNT pathway and bone damage in chronic arthritides 
In a previous study we already showed that, in patients with RA, Dkk-1 is 
significantly increased and associated with a lower BMD and with the presence of 
the typical erosions (32). The positive correlation found between circulating Dkk-
1 and serum C-terminal telopeptide of type I collagen (CTX-I, a marker of bone 
resorption) suggested that the over-production of Dkk-1 (and the resulting 
inhibition of the WNT pathway) may contribute both to the locally increased bone 
resorption and to the impaired bone repair, typical features of the more erosive 
forms of RA (32). This phenomenon may also justify the development of RA-
associated osteoporosis (33).   
On the other hand, AS is a chronic rheumatic disease characterized by the 
inflammation and extensive remodeling of spine and joints. Differently from RA, 
erosive changes are limited in AS, while extensive bone neoformation leads to the 
development of spinal syndesmophytes and extra-articular enthesophytes and 
therefore to joint or spine ankyloses (7). Previous studies already reported that both 
circulating sclerostin and Dkk-1 levels are significantly lower in AS patients when 
compared to matched controls (34–36). The observation of lower circulating levels 
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of WNT inhibitors suggests that WNT overexpression could play a relevant role in 
the focally exuberant bone formation in AS.  
Currently, the WNT pathway is thought to be heavily involved in the pathogenesis 
of bone damage during RA and SA with different and opposite profiles: the 
inhibition of WNT pathway in RA and its overexpression in SA. The influence of 
these inflammatory diseases over the WNT pathway seems to be driven by the 
dysregulation of Dkk-1 and sclerostin.  
Furthermore, we already documented parathyroid hormone (PTH) to be a major 
determinant of Dkk-1 serum levels not only in patients with arthritis but also in 
subjects affected by bone metabolic diseases such as primary hyperparathyroidism 
(32,37,38).  
Similarly to AS, in PsA we can find bone erosive damage often associated with an 
exuberant bone formation, especially in enthesial sites (39).  
In 2017, over the course of my residency, I lead a study  that replicated the finding 
of increased serum levels of Dkk-1 in patients affected by RA (40); our data, along 
with the data from a previous study of our group (32) were also included in a meta-
analysis that confirmed this remark (41).  
In the same study, we demonstrated the presence of decrease d levels of Dkk-1 in 
the PsA cohort, and hypothesized that low levels of Wnt inhibitors could be one 
possible explanation for the pathological bone formation that characterises some 
phenotypes of PsA. 
 
Unanswered questions  
As already discussed, in RA, a disease characterized by overexpression of pro-
inflammatory cytokines (i.e. TNFα, IL-6), OC bone resorption largely prevails upon 
bone formation. Moreover, proinflammatory cytokines have been documented to 
be strong inducers of Wnt inhibitors in RA (42). What would happen after the 
administration of drug with potent antinflammatory activity? 
In PsA, both excess bone resorption and bone formation may coexist and therefore 
we hypothesized that Wnt dysregulation (namely suppressed levels of Wnt 
inhibitors) might explain the presence of a (maladaptive) pro-osteogenic 
environment. The question at this point is: is the hypothesis of a pro-osteogenic 
maladaptive environment applicable also in different settings, such as non-




AIMS OF THE STUDY 
This thesis comprises of three different studies. 
In the first study, we wanted to investigate the changes in Wnt inhibitors and bone 
turnover markers (BTMs), in patients affected by RA receiving treatment with 
either a TNFα inhibitor (certolizumab), or a glucocorticoids (GCs) or an IL-6 
receptor inhibitor (tocilizumab). The study has been published on Calcified Tissue 
International on April 2020 (43). 
In the second study, after having observed the peculiar effects of GCs in RA, we 
studied the same biomarkers in PMR. This study has been very recently published 
on Frontiers in Rheumatology (44). 
In the third study, we investigated several biomarkers (with particular focus on Wnt 
inhibitors and BTMs) associated with the presence of DISH in a cohort of patients 
affected by Type 2 Diabetes Mellitus (T2DM). This final study has been accepted 
for publication on Calcified Tissue International on the 30th September 2020. 
 
MATERIALS AND METHODS 
Study n° 1. Acute effects of glucocorticoid treatment, TNFα or IL-6R blockade 
on bone turnover markers and Wnt inhibitors in early rheumatoid arthritis: a 
pilot study. 
Materials and methods 
We performed a retrospective analysis of prospectively collected data. We enrolled 
in this three-arm study women affected by early RA (< 12 months of symptoms, 
classified according to the ACR/EULAR 2010 criteria (45)) seen at the 
rheumatology outpatient clinic of the University of Verona, Italy. Inclusion criteria 
were: DAS28 ≥ 2.6 despite stable treatment with subcutaneous methotrexate (10-
15 mg/week) for at least 6 months and positive rheumatoid factor and/or anti-
citrullinated protein antibodies (ACPA). We divided the patients depending on the 
treatment started at baseline: 1) patients who started treatment with certolizumab 
pegol with the following schedule: 200 mg weekly subcutaneous administration, 2) 
patients who started treatment with weekly subcutaneous tocilizumab 162 mg, 3) 
patients who started treatment with methyl-predinsolone 8 mg daily. The treatment 
needed to be maintained stable for all the 4 weeks. All groups continued 
methotrexate at the current dose. 
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Exclusion criteria were: treatment with glucocorticoids within the last 3 months of 
enrolment, treatment with bisphosphonates or denosumab within the last 2 years, 
or with other drugs known to affect bone metabolism or fracture risk; onset of 
menopause within 2 years or onset of the climacteric period during the study; and 
the presence of renal, liver, endocrine, heart, and metabolic bone diseases. Every 
patient received also 1,000 UI vitamin D and 1 g calcium per day; the dose could 
not be changed. DAS28 was recorded at baseline and after 4 weeks. 
 
Study n° 2. Wnt inhibitors and bone turnover markers in patients with 
polymyalgia rheumatica and acute effects of glucocorticoid treatment 
Materials and methods 
We performed a prospective study on consecutive patients affected by PMR 
classified according to the 2012 EULAR/ACR criteria (46) and evaluated at the 
rheumatology outpatient clinic of the University of Verona. Exclusion criteria were: 
1) treatment with glucocorticoids within the previous 3 months, 2) history of 
osteoporosis, 3) treatment with bisphosphonates or denosumab within the previous 
2 years, or with other drugs known to affect bone metabolism or fracture risk and/or 
4) history of any renal, liver,  heart,  thyroid, and metabolic bone diseases 
potentially interfering with the objective of this study. Previous supplementation 
with cholecalciferol was not an exclusion criterion. Every patient received (if not 
already taking) 1,000 UI vitamin D and 1 g calcium per day; the dose could not be 
changed during the whole period of observation. After being diagnosed with PMR, 
patients were prescribed methylprednisolone 16 mg daily for the first four weeks 
(the duration of the study), according to current recommendations (47). PMR 
activity score (48) was adopted to assess disease activity at baseline and at week 4. 
The time frame of the study was limited to the first four weeks because after the 
first month all patients started an antiresorptive treatment according to national 
guidelines (49). 
The subjects of the healthy controls (HC) group, matched for sex and age, were 
enrolled from retired hospital personnel. A single blood sample of HC was taken. 
The study was conducted within the protocol 1483CESC approved by our local 
Ethics Committee, in accordance with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. Written informed consent was 




Biochemical analysis, study 1 and 2. 
All blood samples were collected in the morning after overnight fasting at baseline, 
at week 1 and week 4. The samples were stored upon collection and at −50 °C and 
finally assayed, in single batch, for intact parathyroid hormone (iPTH), 25OH-
vitamin D (25OHD), N-propeptide of type I collagen (PINP), C-terminal 
telopeptide of type I collagen (β-CTX-I), sclerostin and Dkk-1. All the samples 
were processed in the laboratory of the Rheumatology Unit of the University of 
Verona. Bone turnover markers (PINP and β-CTX-I), 25OHD and iPTH were 
measured by the IDS-ISYSMulti-Discipline automated analyzer 
(Immunodiagnostic System, Boldon, UK) based on chemiluminescence 
technology. The coefficients of variation (CV) intra-assay measured in our 
laboratory were 4% for PINP (inter-assay CV 6%), 3% for β-CTX-I (inter-assay 
CV 7%), 6% for 25OHVITD (inter-assay CV 9%) and 2,7% for iPTH (inter-assay 
CV 5,5%). 
Serum Dkk-1 and sclerostin were measured by ELISA (Biomedica 
Medizinprodukte, Vienna, Austria) with a sensitivity of 1.7 and 3.2 pmol/L and 
intra-assay CV of 7 and 5% (inter-assay CV 8.2% and 6.9%) respectively. 
 
Study n° 3. Diffuse idiopathic skeletal hyperostosis (DISH) in type 2 diabetes: 
a new imaging possibility and a new biomarker 
Materials and Methods 
For this study, we enrolled 96 post-menopausal women with established T2DM, 
who consecutively attended our diabetes outpatient clinic of the University of 
Verona over a period of three months. All these women met the following inclusion 
criteria: (a) age ≥50 years; (b) Caucasian; (c) post-menopausal (physiological or 
surgical); (d) glucose-lowering treatment with diet alone or in combination with 
oral agents (but not with insulin therapy); and (e) no self-reported history of 
osteoporosis, osteoporotic fractures, treatment with bisphosphonates and other anti-
osteoporotic agents, as well as steroids or hormone replacement therapy.  
We excluded patients with: (a) history of significant alcohol consumption (i.e., >20 
grams of alcohol per day) or competing causes of chronic liver disease (e.g., virus, 
drugs, autoimmunity, hemochromatosis); (b) history of cirrhosis of any aetiology, 
active cancer and end-stage renal disease (defined as estimated glomerular filtration 
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rate <15 ml/min/1.73 m2 or dialysis); and (c) history of hyperthyroidism or 
hypothyroidism. 
The study was conducted within the protocol 1483CESC approved by our local 
Ethics Committee, in accordance with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. Written informed consent was 
obtained from all participants included. 
Clinical and laboratory variables 
BMI was measured as kilograms divided by the square of height in meters. Waist 
circumference was measured at the midpoint between the lowest rib and the iliac 
crest. Blood pressure was measured with a standard sphygmomanometer after the 
patient had been seated quietly for at least 5 minutes. Patients were considered to 
have hypertension if their blood pressure was ≥140/90 mmHg or if they were taking 
any anti-hypertensive therapy. Information on the type of menopause 
(physiological or surgical), smoking history and current use of medications 
(including use of vitamin D supplements) was obtained interviewing all patients 
during medical examinations.  
Venous blood samples were drawn in the morning after an overnight fast. 
Measurements of serum glucose, lipids, creatinine (measured using a Jaffè rate 
blanked and compensated assay), high-sensitivity C reactive protein (hs-CRP) and 
other biochemical blood parameters were obtained using standard laboratory 
procedures at the central Laboratory of our hospital. LDL-cholesterol was 
calculated using the Friedewald’s equation. Hemoglobin A1c (HbA1c) was 
measured by the high-performance liquid chromatography analyzer Tosoh-G7 
(Tosoh Bioscience Inc., Tokyo, Japan). Homeostasis model assessment (HOMA-
IR) score was used for estimating insulin resistance.  
Chronic kidney disease (CKD) was defined as the presence of eGFRMDRD <60 
mL/min/1.73 m2. Pre-existing history of ischemic heart disease (IHD) or stroke was 
defined as a documented history of myocardial infarction, angina, coronary 
revascularizations or ischemic stroke.  
Serum bone turnover biomarkers 
Serum samples were collected from all patients at the time of study recruitment, 
centrifuged, separated and stored at -80°C until measurement. In total, we tested 16 
different serum biomarkers; an expert laboratory technician, who was blinded to 
12 
 
patients’ clinical details, measured 25-hydroxyvitamin D3 [25(OH)D], intact 
parathyroid hormone (PTH) and a number of indirect bone turnover biomarkers, 
such as sclerostin, C-terminal telopeptide of type 1 collagen (sCTX), procollagen 
type 1 N-terminal propeptide (P1NP), Dickkopf-related protein-1 (Dkk-1) and 
soluble ligand of the kappa-B factor activator receptor (RANKL). Specifically, 
25(OH)D, PTH, sCTX and P1NP were measured using the IDS-ISYS Multi 
Discipline Automated Analyzer (Immunodiagnostic System, Boldon, UK) 
employing immuno-chemiluminescent technology, whilst Dkk-1, sclerostin and 
RANKL were measured by commercially available enzyme immunoassay ELISA 
kits (Biomedica Medizinprodukte, Vienna, Austria) on the fully automated 
microplate analyser Personal LAB (Adaltis, Rome, Italy). The intra-assay 
coefficients of variation (CV), in our laboratory, were 3% for P1NP (inter-assay 
CV 6%), 3% for sCTX (inter-assay CV 7%), 5% (inter-assay CV 6.9%) for 
sclerostin, 7% for Dkk-1 (inter-assay CV 8.2%), 2.7% for PTH (inter-assay CV 
5.5%), 6% for 25(OH)D (inter-assay CV 9%), and < 10% (inter-assay CV <12%) 
for RANKL, respectively. 
Dual energy X-ray absorptiometry 
A DXA scan was performed in all patients using the GE Lunar iDXA 194 system 
(GE Healthcare Lunar, Madison, WI, USA) by a single expert operator, who was 
blinded to patients’ clinical details. We obtained BMD measurements (g/cm2) and 
T-scores at both lumbar spine (L1-L4) and femur (neck and total). Total body 
densitometry was performed measuring body composition, i.e., fat mass (FM) and 
fat-free mass (FFM). VFA was performed in all patients in order to detect the 
presence of any vertebral fractures and/or DISH. 
Diagnosis of DISH was established based on Resnik criteria [10], however we 
adopted VFA and not X-rays as originally meant. Two expert operators (G.A. and 
R.N.) examined independently 200 selected VFA images for the diagnosis of DISH, 
and the interobserver Cohen’s kappa coefficient was 0.77. Both operators, blinded 
to patients’ clinical details, then performed VFA assessment for the diagnosis of 
DISH on the images of all 96 patients of the current study, with an inter-observer 
Cohen’s kappa coefficient of 0.747. The discordant cases were then discussed until 
complete agreement was attained. 
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When available, X-rays of the thoracic and lumbar spine performed in the last 12 
months (for any reason) were retrieved and assessed by a radiologist expert in 
musculoskeletal conditions. 
 
Statistical analysis (all studies) 
Normality for all variables was tested by Shapiro-Wilk test. Data are presented as 
means ± SD for normally distributed variables and medians (inter-quartile-ranges 
[IQR]) for non-normally distributed variables.  
Study n° 1. Baseline comparisons and follow-up comparisons of continuous 
variables between groups, in terms of changes in serum biomarkers over time, were 
made with the use of analysis of variance (ANOVA) and post-hoc tests (corrected 
with Holm-Bonferroni for multiple comparisons). The variation of each marker was 
tested for the null hypothesis of no variation after treatment administration with a 
one-sample t test (test vs zero). 
Study n° 2. A statistical power analysis was performed for sample size estimation. 
The sample size was based on the assumption that a ≥15% decrease in the values 
of Dkk-1 after 4 weeks of treatment with GC was found. This assumption was based 
on the data of a previous study in RA (43). We calculated a required sample size as 
n = 14, with an alpha = .05 and power = 0.80. 
The differences between the values of the different parameters tested between PMR 
and HC at any observation point were analyzed by t test for normally distributed 
variables and Mann-Whitney U test for independent samples for non-normally 
distributed variables. 
Study n° 3. After stratification of patients by presence or absence of DISH the 
differences in main clinical and biochemical characteristics between the two groups 
were tested by using the Student’s t test for normally distributed variables and the 
Mann-Whitney U test for independent samples for non-normally distributed 
variables. T-scores and Z-scores (the number of standard deviations above or below 
the mean for the patient's age, sex and ethnicity) measured by DXA at lumbar spine, 
femoral neck and total hips. Z-scores were tested vs 0 via one sample t-test in order 
to assess whether the BMD were higher than expected (as known, 0 represents the 
average Z-score of sex, age and ethnicity-matched healthy population). Differences 
in the proportion of comorbid conditions and use of cholecalciferol 
supplementation in the DISH and no-DISH groups were tested by the Fisher’s exact 
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test. Adjustment for potentially confounding factors (i.e. age and years since 
menopause) between the DISH and no-DISH groups of patients was performed by 
binary logistic regression.  
Given the exploratory nature of the study, we chose not to adjust for multiplicity. 
Two-sided p values of 0.05 or less were considered to be statistically significant. 




Study n° 1. Acute effects of glucocorticoid treatment, TNFα or IL-6R blockade 
on bone turnover markers and Wnt inhibitors in early rheumatoid arthritis: a 
pilot study. 
Data were obtained for 14 patients treated with certolizumab pegol, 14 patients 
treated with tocilizumab and 20 patients treated with methyl-prednisolone. No 
difference in any of the tested parameters was found at baseline (table 1).  
 Methyl-
prednisolone 
(N = 20) 
Tocilizumab 
(N = 14) 
Certolizumab 
pegol (N = 14) 
ANOVA 
Age 62.3 ± 8.4 60 ± 9.8 58.3 ± 8.4 Ns 
DAS28 4.1 ± 0.9 3.9 ± 0.7 4.05 ± 0.7 Ns 
25OHD (ng/ml) 26.3 ± 5.7 33.1 ± 9.0 32.3 ± 13.2 Ns 
PTH (pg/ml) 34.2 ±12.5 40.7 ± 15.0 30.6 ± 11.6 Ns 
PINP (ng/ml) 42.3 ± 16.0 39.9 ± 24.7 34.2 ± 15.0 Ns 
β-CTX-I (ng/ml) 0.397 ± 0.212 0.301 ± 0.212 0.295 ± 0.159 Ns 
Dkk-1 (pmol/l) 46.9 ± 22.2 50.0 ± 16.6 38.7 ± 11.8 Ns 
Sclerostin (pmol/l) 34.2 ± 12.6 31.5 ± 10.5 29.4 ± 10.6 Ns 
 
Table 1. Baseline characteristics of the patients. Data expressed as mean ± standard deviation. 
ANOVA, Analysis of Variance; DAS28, Disease Activity Score-28; 25OHD, 25-hydroxy vitamin 
D; PTH, parathyroid hormone; PINP, N-terminal propeptide of type I procollagen; β-CTX-I, C-






DAS28 was assessed after 4 weeks, and it showed improvement from baseline, 
however without any statistically significant difference among the three groups 
(data not shown). 
β-CTX-I decreased significantly vs baseline (p<0.05) only in the group treated with 
certolizumab pegol, at week 1 (-27% ± 21.5) and week 4 (-28.2% ± 26.2), both were 
resulted statistically significant when compared with tocilizumab (p<0.05). 
PINP decreased significantly vs baseline (p<0.05) in the group treated with methyl-
prednisolone at week 1 (-16.1% ± 15.6) and week 4 (-27.2% ± 15.3), both were 
resulted statistically significant when compared with both tocilizumab and 
certolizumab pegol (p<0.05). PINP increased significantly vs baseline (p<0.05) in 
the group treated with certolizumab pegol at week 1 (33.9% ± 20.4) and week 4 
(45.6% ± 46.2), both were resulted statistically significant when compared with 
both tocilizumab and methyl-prednisolone (p<0.05). 
Dkk-1 and sclerostin decreased significantly vs baseline (p<0.05) in the group 
treated with certolizumab pegol, at week 1 (-50.0% ± 13.2 and -30.1 ± 30.4, 
respectively) and week 4 (-47.5% ± 18.1 and -31.1% ± 18.0, respectively). 
Treatment with methyl-prednisolone produced a significant decrease vs baseline of 
Dkk-1 (p<0.05) at week 1 (-9.4% ± 21.6) and week 4 (-8.5% ± 24.3), and of 
sclerostin at week 4 (-10.4% ± 24.3, p<0.05 vs tocilizumab). Tocilizumab did not 
result into any significant variation for Wnt inhibitors. The percent changes of the 
serum levels of bone turnover markers, Dkk-1 and sclerostin are reported in figure 
1. No significant changes were found over the four weeks for PTH and 25OHD 






Figure 1: Bone turnover markers and Wnt inhibitors percent changes after 1 and 4 weeks of 
treatment. Data are expressed as mean ± SE; PINP, N-terminal propeptide of type I procollagen; β-
CTX-I, C-terminal telopeptide of type I collagen; W1, week 1; W4, week 4. 
 a p<0.05 vs tocilizumab; b p<0.05 vs methyl-prednisolone; c p<0.05 vs baseline.  
 
 
Study n° 2. Wnt inhibitors and bone turnover markers in patients with 
polymyalgia rheumatica and acute effects of glucocorticoid treatment 
Results 
We enrolled a total of 17 patients affected by PMR (7 males and 10 females) and 
17 HC (7 males and 10 females). Median disease duration was 3 [2-4] months. 








 HC group 
(N = 17) 
PMR group (N = 18) 
 (Single observation) Baseline W4 
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Age, mean (SD) 76.3 (8.1) 78.3 (8.6) / 
Gender (M:F) 7:10 7:10 / 
BMI mean (SD) 26.1 (2.4) 24.9 (2.4) / 
CRP, median (IQR) mg/L / 41 (20-51) 3 (3-3.5) d 
PMR AS / 30.1 (25.9-33.2) 6.5 (6.3-7.3) d 
PINP, mean (SD) ng/mL 52.8 (20.8) 59.0 (17.0) 34.4 (12.1) b, d 
CTX-I, median (IQR) ng/mL 0.395 (0.287-0.494) 0.340 (0.302-0.45) 0.268 (0.19-0.423) 
a (p=0.049), c  
Dkk-1, median (IQR) pmol/L 21.5 (15.2-31.1) 33.6 (29.7-42.0) b 23.9 (16.4-40.3) c  
Sclerostin, mean (SD) 
pmol/L 
44.7 (19.6) 41.9 (15.2) 26.9 (9.2) b, d 
 
Table 2: baseline and follow up values of the parameters for healthy controls (HC) and patients with 
polymyalgia rheumatica (PMR). Abbreviations: HC, healthy controls; PMR, polymyalgia 
rheumatica; W, week; SD, standard deviation; IQR, interquartile range; BMI, body mass index, 
CRP, C-reactive protein, PMR AS, , polymyalgia rheumatica activity score, PINO, N-propeptide of 
type I collagen; CTX-I, C-terminal telopeptide of type I collagen. 
a p <0.05 vs HC 
b p <0.01 vs HC 
c p < 0.05 vs baseline 










At baseline, only Dkk-1 was significantly higher in the PMR group (p=0.002) than 
in HC (Table1).  Changes from baseline to week 4 regarding BTM, Dkk-1 and 
sclerostin for the PMR group are depicted in figure 2. 
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After 4 weeks of GC treatment all patients were in clinical remission and CRP 
values turned to normal. Concerning markers of bone metabolism, we found in the 
PMR group a decrease of PINP (mean ± SD percentage decrement as compared to 
baseline -40±18.6%, p = 0.000), CTX-I (-23.5±41.3%, p = 0.032), Dkk-1 (-
22.4±39.6, p = 0.033) and sclerostin (-32.49±20.47, p < 0.001) as compared to 
baseline levels.  
A significant positive correlation was found between the percentage decrease in 








Study n° 3 - Diffuse idiopathic skeletal hyperostosis (DISH) in type 2 diabetes: 
a new imaging possibility and a new biomarker 
Results 
Overall, we studied a total of 96 post-menopausal women with non-insulin-treated 
T2DM (mean ± SD age: 72.7±8.5 years; median duration of diabetes: 10.5 [6-17] 
years; median body mass index (BMI): 29 [26-31] kg/m2; median hemoglobin A1c 
(HbA1c): 51 [48-57] mmol/mol). The main clinical and biochemical characteristics 












Age (years) 72.7 ± 8.5 75.4 ± 6.5 70.61 ± 8.5 0.02 
Age at menopause 
(years) 
49.9 ± 0.2 49.1 ± 0.5 49.8 ± 0.3 Ns 
Years since 
menopause (years) 
22.5±9 26.35 ± 6.78 20.7 ± 8.5 0.008 






98 [90-105] 95.5 [88.5-
106.5] 
98 [90-105] Ns 
















140 ± 16 144 ± 11 139 ± 17 Ns 
Diastolic blood 
pressure (mmHg) 
76 ± 9 73 ± 7 77 ± 9 Ns 
Diabetes duration 
(years) 
10.5 [6-17] 15 [6.25-21.7] 10 [6.0-16.0] Ns 
HbA1c 
(mmol/mol) 
51 [48-57] 50 [48-57] 50 [48-55] Ns 



























32 [23.4-38.0] 35.5 [27.7-
49.5] 
0.010 





















64.5 [57-80.5] 63 [56-73] Ns 
Total cholesterol 
(mg/dl) 












78 [54.2-91.7] 74 [57-102] Ns 
HDL-cholesterol 
(mg/dl) 
60 ± 13.4 59.2 ± 12.8 59.6 ± 13.8 Ns 
Uric acid (mg/dl) 4.4 ± 1.3 4.87 ± 1.15 4.43 ± 1.4 Ns 
HOMA-IR score 2.26 [1.26-
3.79] 





0.67 ± 1.3 0.68 ± 1.50 0.51 ± 1.35 Ns 
T-score lumbar 
spine 
-0.81 ± 1.46 -0.79 ± 1.35 -0.76 ± 1.47 Ns 
Z-score femoral 
neck 
0.10 ± 0.84 -0.01 ± 0.73 0.12 ± 0.88 Ns 
T-score femoral 
neck 
-1.51 ± 0.99 -1.77 ± 0.68 -1.45 ± 1.05 Ns 
Z-score total hip 0.71 ± 1.0 0.74 ± 0.85 0.70 ± 1.08 Ns 




40.6% 60% 35.5% 0.04 
 
Table 3. Main clinical and biochemical characteristics of postmenopausal type 2 diabetic women 
stratified by presence or absence of DISH.  Data are expressed as means ± SD for normally 
distributed variables and medians [IQRs] for non-normally distributed ones. 
 
From the patients’ electronic medical records, previous spine X-rays were retrieved 
in 10 patients with DISH and in 100% of the cases the diagnosis made at VFA was 
confirmed. Examples of DISH documented by VFA and respective X-rays are 





Figure 3. Two cases of DISH as documented by DXA-VFA and respective X-rays in two different 
type 2 diabetic women (patient A and patient B). X-Rays are reported on the left and VFA on the 
right, respectively. 
 
Overall, 20 patients (20.8%) showed features of DISH, whilst 8 (8.3%) had 
vertebral fractures. The distribution of spinal involvement according to the 
individual vertebral body level is shown in figure 4.  
 
 
Figure 4. Distribution of spinal involvement according to individual vertebral body level. 
 
In addition, 3 patients showed both features of DISH and presented at least one 
vertebral fracture. 11.9% of the subjects were osteoporotic at the lumbar spine, 4% 
at femoral neck and 4% at total hip. BMD values, expressed as Z-scores, showed 
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positive (> 0) mean values. In particular, they showed statistically significant higher 
values at all sites: 0.58 ± 1.38 at lumbar spine (for Z-score tested vs. 0 p = 0.0001), 
0.10 ± 0.88 at femoral neck (p=0.0001), 0.72 ± 1.06 at total hip (p =0.0001). No 
significant differences in BMD values, expressed as Z-scores, were found between 
the DISH and no-DISH groups (table 3). The two groups of patients were 
significantly different only for age, years since menopause, hypertension 
prevalence, proportion of patients taking cholecalciferol supplements and serum 
sclerostin levels. In particular, women with DISH were more likely to be older and 
had higher years since menopause and lower serum sclerostin levels than those 
without DISH. Notably, after adjusting by age and years since menopause, serum 
sclerostin levels remained significantly lower amongst those with DISH (figure 5). 
In the binary logistic regression model including serum sclerostin, age and years 
since menopause, only sclerostin resulted to be a statistically significant predictor 
(OR 0.93 95%CI 0.88-0.98, p = 0.006). Age and years since menopause were not 
significant (OR 0.98 95%CI 0.78-1.24 and OR 1.14 95%CI 0.90-1.4, respectively). 
 
Figure 5. Mean serum sclerostin levels in DISH (black bars) and no-DISH (white bars) 
postmenopausal women with type 2 diabetes, before and after adjustment either for age or for age 
plus years since menopause. Error bars show 95% confidence intervals. 
 
 
The proportion and comparison of the recorded comorbid conditions between DISH 
and no-DISH patient groups are reported in figure 6. A statistically significant 
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imbalance between the two groups was found only in the proportion of patients 
affected by hypertension (p = 0.035), but this significance was lost after adjustment 
for age. 
The proportions of patients taking cholecalciferol supplementation is reported in 
table 1. Their median cholecalciferol daily dose was 1,000 IU, interquartile range 
800-1,600 IU. No statistically significant differences in terms of age or serum 
sclerostin were found between the supplemented vs non-supplemented subgroups 
(data not shown). 
 
 
Figure 6. Proportion of patients presenting comorbid conditions in DISH and no-DISH groups. 
After adjustment for age, no significant differences were found for any condition between the two 






Study n° 1. Acute effects of glucocorticoid treatment, TNFα or IL-6R blockade 




The goal of this study was to compare the acute effects of drugs with different 
mechanisms of action on bone turnover markers and on modulators of the canonical 
Wnt pathway. Our decision to focus on the short-term effects has been suggested 
by the fact that bone is programmed to defend its health through the coupling of 
bone formation following bone resorption (42).  Indeed, bone undergoes a limitless 
process of turnover where the activity of bone resorbing cells is overlapping by the 
activity of  bone forming ones (42). This complex mechanism of coupling allows 
the skeletal tissue quickly to respond to physiological and pathological stresses 
(42).  In this study, our objective was to investigate the early direct effects of various 
pharmacological treatments before the onset of any possible contra-regulatory 
mechanism. 
The most striking finding of our study is the marked effect of the anti-TNFα 
treatment when compared to the IL-6 blockade and the daily glucocorticoid 
treatment at moderate dosage (methyl-prednisolone 8 mg daily).  
We found a relevant decrease in β-CTX-I serum levels and an increase in PINP 
after one week of treatment with anti-TNFα, while we did not detect any significant 
change in β-CTX-I either in the anti-IL-6R or in the methyl-prednisolone arms. We 
also observed a decrease in PINP with methyl-prednisolone, in line with previous 
studies (50,51).  
Despite the renown effects of glucocorticoids on bone resorption, we did not 
observe any change in β-CTX-I serum levels in the methyl-prednisolone arm (52). 
However, we should note that, in RA, serum levels of inflammatory reactants are 
more strongly correlated with bone resorption than with bone formation markers 
(53,54). For this reason, the lack of changes in serum β-CTX-I during 
glucocorticoid treatment could be explained by its beneficial effect on 
inflammation, which might counterbalance the increase in bone resorption. Another 
possible explanation is that glucocorticoids have a predominant negative effect on 
osteoblasts and bone formation. Nonetheless, the suppression of bone formation 
demonstrated with the use of glucocorticoids is particularly evident later in the 
treatment course, while in the first few months of therapy an increase in bone 
resorption is more conspicuous.  
Regarding the effects of TNFα inhibitors, our data on BTMs are consistent with the 
literature. Previous studies with these biologic agents observed a decrease in 
markers of bone resorption and an increase in markers of bone formation (55,56). 
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The present study, along with a recently published experience from our group (55), 
is currently the only report on the acute changes occurring within the first month of 
treatment. The expected decrease in β-CTX-I witnessed in the certolizumab pegol 
arm was not seen with IL-6R blockade, despite its potent anti-inflammatory effects. 
Presently, we cannot provide a certain explanation for this discrepancy, but we 
hypothesize an earlier influence on bone metabolism exerted by TNFα inhibitors 
(or specifically by certolizumab pegol) than tocilizumab.  
Furthermore, the data from the literature on changes in bone resorption induced by 
IL-6R inhibitors are still inconsistent [8,9,16–18], while two studies reported an 
increase in PINP [9,18]. In both studies however, PINP was dosed after three 
months of treatment. 
Data concerning glucocorticoids and Wnt inhibitors are also not very consistent, 
and the various studies involved patients affected by different diseases and 
receiving treatment with disparate doses of glucocorticoids. In experimental studies 
in rodents and cell cultures glucocorticoids have been reported to increase the 
expression of sclerostin and Dkk-1 (57). The inhibition of bone formation and the 
increase in bone resorption following corticosteroid treatment has been linked to 
multiple mechanisms (i.e., the  increased expression of sclerostin)  (58).  
The role of sclerostin is supported by an interesting genetic study that showed that 
glucocorticoids led to impairment of the bone mass, microarchitecture and strength 
only in wild-type mice but not in female mice lacking sclerostin (59). Furthermore, 
the treatment with an antibody neutralizing sclerostin has been showed to prevent 
the loss of bone mass and bone strength induced by glucocorticoids through the 
preservation of osteoblast activity (60). These findings are not in line with the 
results of our study that shows a decrease in sclerostin. However, in the previous 
studies, the influence of the condition for which glucocorticoid treatment was 
required has not been addressed. Indeed, in 17 glucocorticoids-naïve patients, this 
treatment induced an acute significant reductions of sclerostin (50). Another study 
regarding 91 patients with systemic autoimmune diseases who started 
glucocorticoids reported contradictory changes of Wnt antagonists: serum levels of 
sclerostin and Dkk-1 increased significantly during the first week of therapy but 
from the second week onward, they decreased (61). A possible explanation for the 
reduction in sclerostin serum levels could be the apoptosis of osteocytes caused by 
glucocorticoids (62). On the other hand, several studies have reported that the 
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elevated levels of pro-inflammatory cytokines in inflammatory diseases (such as 
the ones requiring corticosteroid therapy) can also cause osteocyte apoptosis (63). 
In this way, corticosteroid treatment may act in two ways: directly, by reducing 
sclerostin trough osteocyte apoptosis, or indirectly (in inflammatory conditions), by 
limiting the reduction of sclerostin due to the osteocyte apoptosis caused by pro-
inflammatory cytokines. 
The changes of Dkk-1 during glucocorticoids in patients affected by arthritis are 
also not consistent in the literature. 
In a recent study on mice, Colditz et al [12] showed that osteocyte-specific Dkk-1 
deletion did not affect the bone loss induced by arthritis, but it assured an evident 
protection by glucocorticoid-induced bone loss. 
However, we should remember that Dkk-1 is produced not only by osterix-
expressing osteoprogenitors but also by synovial fibroblast of patients with early 
arthritis [28]. Therefore, also Dkk-1 might change in opposite directions according 
to the setting. It may increase (as a direct effect on osteoprogenitors) in some 
conditions needing glucocorticoid treatment (i.e., pulmonary diseases) as a direct 
effect on the productive osteoprogenitor cells. However while it may decrease (due 
to the inhibition of inflammation on synovial fibroblasts) in RA, a disease in which 
its serum levels are greatly upregulated (41). All the patients included in this study 
were affected by RA and thus the decrease in Dkk-1 is somewhat expected.  
In a previous study we documented the effects of the TNFα blockade on Dkk-1 and 
sclerostin (55,64). The decrease of Dkk-1 after TNFα inhibition is expected, as 
Dkk-1 is increased in patients with RA (40,41) and its expression is also induced 
by TNFα in vitro and in vivo (65,66).  
The reduction in sclerostin serum levels in the anti-TNFα and methyl-predinsolone 
group, consensual with the Dkk-1 decrease, might also contribute to explain the 
reduction of bone and cartilage damage (67). Sclerostin, commonly considered an 
osteocyte-specific protein (68), is also expressed by chondrocytes (67), and can 
contribute to the pathogenesis of both inflammatory bone and cartilage damage 
(68). However, it should be pointed out that the interpretation of this data is limited, 
as it is unclear to what extent serum concentrations of sclerostin correlate to local 
cytokine production, or action, within the cartilage and bone microenvironment. 
Two studies investigated the changes of Wnt inhibitors during treatment 
tocilizumab (69,70). Both showed a decrease in Dkk-1 serum levels after two or 
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three months of treatment. We have reported data on serum Dkk-1 and sclerostin 
changes within the first month of treatment and, differently from previous 
experiences, no significant changes were observed for both markers after IL-6R 
blockade. This remark might be explained by a slower influence of the treatment 
on the Wnt pathway, in line with lack of changes on BTMs discussed previously. 
Interestingly, a pre-clinical study suggested a different regulation of Wnt inhibitors 
between TNFα and IL-6 (71), with IL-6 showing a suppressive effect on Dkk-1 
production. Therefore, the apparently stable levels of these markers might also be 
the result of mechanisms pointing in different directions, namely the induction of 
Dkk-1 from IL-6R blockade and its inhibition due to suppression of inflammation. 
Nevertheless, further studies are needed to investigate the interplay between IL-6R 
inhibition and the extent and the timing of its effects on this pathway. 
Data on sclerostin changes after tocilizumab therapy are currently scarce and not 
consistent. One study (70) reported an increase in sclerostin at two months, while 
another one reported no significant change (69). Biopsies from bone replacement 
surgery (72) showed that osteocyte of RA patients express high levels of sclerostin 
but are also characterized by high death rates. This may lead sclerostin serum levels 
to depend on both osteocyte expression and their overall number. Indeed, serum 
evaluation of sclerostin, which is mainly expressed by osteocytes (73), needs to be 
carefully interpreted.  
When considered altogether, our data seem to suggest a marked effect on BTMs 
and Wnt inhibitors induced by the inhibition of TNFα and the absence of detectable 
changes by IL-6R blockade within the first four weeks. Glucocorticoid treatment 
seems to settle somewhere between the two, with a unique (and arguably undesired) 
detrimental effect on bone formation.  
TNFα and IL-6R inhibition have both shown to slow erosive progression (74) and 
to preserve or increase spine and hip Bone Mineral Density (BMD) (56,69,75–78). 
Glucocorticoids also have shown to reduce localized bone loss and joint damage in 
patients with recent-onset active RA (79), while for systemic bone loss their effect 
is probably condition and dose dependent. Indeed, the systemic negative effects of 
glucocorticoid on BMD are renown (52), but there are also clinical trials on RA 
patients that support a beneficial effect of low-dose glucocorticoid treatment on 
systemic BMD (80,81). These seem to be associated with a rapid and aggressive 
suppression of inflammation which may outweigh their negative influence on bone 
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health (79). Therefore, the interaction between the direct and indirect effects on 
bone and systemic inflammation (when present) must always be addressed when 
investigating bone metabolism and its fine regulators (i.e., Dkk-1 and sclerostin). 
Our study has some limitations. It is a retrospective analysis and therefore we 
cannot completely exclude the risk of confounding variables which might have 
biased the three samples, despite the matching for age, disease activity and bone 
parameters. Second, the sample size is limited. Third, data on radiographic damage 
were not available. One last limitation is represented by lack of data regarding the 
assessment of physical activity before and after the treatment. According to the 
literature, mechanical loading on the skeleton may influence sclerostin levels (82). 
In conclusion, TNFα inhibition strongly and quickly influences BTMs and Wnt 
inhibitors. Such findings were not observed with IL-6R blockade, at least within 
the first four weeks of treatment.  
It should be noted that our exploratory study cannot give the explanation of the 
different effects of anti TNFα treatment than tocilizumab. In fact, it merely 
describes, for the first time, a peculiar effect on the short-term. We cannot exclude 
that this might be attributable to a more direct role of the TNFα than IL6 on the 
regulation of bone metabolism 
Glucocorticoids at moderate dosage exert similar, albeit less marked, changes, 
perhaps linked to the reduction of inflammation, nonetheless they still show some 
undesired effects on bone metabolism, namely the suppression of bone formation. 
 
Study n° 2. Wnt inhibitors and bone turnover markers in patients with 
polymyalgia rheumatica and acute effects of glucocorticoid treatment 
This is the first study that investigated BTM and Wnt inhibitors in patients affected 
by PMR at baseline and after four weeks of treatment with GC.  
Our data demonstrate that in treatment-naive PMR patients, Dkk-1 are increased 
when compared with HC. In addition, the decrease of systemic inflammation after 
4 weeks of GCs (all patients were in clinical and laboratory remission at that time) 
is associated with a decrease in Wnt inhibitors (Dkk-1 and sclerostin), CTX-I and 
in PINP.  
The finding of increased levels of Dkk-1 in untreated PMR patients is not 
surprising. Indeed, it is consistent with similar observations in RA, arguably the 
most common rheumatic inflammatory disease (40,41,83). Pro-inflammatory 
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cytokines such TNFα and IL-6 play a fundamental role in the pathogenesis of 
inflammation and bone loss in RA, partly due to the exaggerated production of Dkk-
1 and other Wnt antagonists (84,85). Consistent with this model, treatments with 
TNFα inhibitors or GC by reducing pro-inflammatory cytokines in RA patients 
have been shown to rapidly decrease Dkk-1 (and sclerostin) serum levels 
(43,55,86,87). Given the central pathogenetic role of TNFα and especially IL-6 in 
PMR (88) a similar model might be applied to interpret the dysregulation of the 
Wnt system in this disease, and the reduction of its inhibitors that we observed with 
CG treatment. The significant positive correlation we found between the decrease 
of CRP and Dkk-1 seems to support this conclusion. 
While the normalization of Dkk-1 after 4 weeks of GC treatment can be explained 
mainly by the link between inflammation and excessive Wnt inhibition, the 
reduction of sclerostin even below the levels of HC could be due to the direct effects 
of GC on this molecule. In a recent study, Thiele et al (89) reported not only an in 
vitro decrement of sclerostin expression after GC treatment in human bone marrow 
stromal cells, but also found decreased serum sclerostin in a cross-sectional 
observation of 21 patients with long lasting (average duration of 1.31 years) PMR 
who received chronic treatment with GC. Previous studies on autoimmune diseases 
different from PMR support the presence of contradictory effects of GC on Wnt 
antagonists (90,91). It is therefore possible that the suppressive effect of GC on 
sclerostin expression in PMR could be twofold: an indirect effect via the inhibition 
of inflammation (similarly to Dkk-1), and a direct effect, independent from disease 
activity and inflammation, on cells of the mesenchymal lineage (i.e. osteocytes) 
(89).  
In our study, PINP but also CTX-I yielded a significant decrement after 4 weeks of 
GCs not only with respect to baseline levels but also with respect to HC, even if at 
baseline, levels were comparable between patients and HC (a lack of statistical 
power in this regard can certainly not be excluded). Inflammatory rheumatic 
conditions can be associated with both local and systemic bone resorption due to 
the pathologic increases of proinflammatory cytokines and mediators (42). In this 
case however, levels of CTX-I should have been higher in PMR patients than HC 
at baseline. Suppression of pathologic inflammation is therefore expected to have 
positive effects in this setting, both via the suppression of proinflammatory 
cytokines and via the already discussed reduction in Dkk-1 and sclerostin, with 
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subsequent positive effects on the regulation of the RANKL/OPG ratio (42). 
However, it should be noted that the absolute serum levels of CTX-I at week 4 were 
lower than those of HC. In this regard, a relationship between the decrease in bone 
resorption and the marked suppression of sclerostin might be speculated, albeit a 
counter regulatory homeostatic response to the decrease in PINP, often seen during 
treatment with osteoactive drugs (42), cannot be ruled out. 
Indeed, we also observed a decrease in PINP with GC that is in line with previous 
studies (43,50,51) and confirms the renown (direct) detrimental effects of GC on 
osteogenesis and bone formation. Given the suppression of Dkk-1 and sclerostin, 
the impairment of the bone anabolic activity suggested by the decrease in PINP 
appears to be largely independent from the Wnt system. Our observations seem to 
be in line with the concept of a direct “toxic” role of GC towards cells of the 
osteoblastic lineage and their precursors, resulting in a deficiency in bone forming 
surfaces (42,92).  
 Our study has several limitations. First of all, sample size was limited. The 
sensitivity analysis was calculated on the expected changes of Wnt inhibitors, and 
therefore it was not powered to rule out, for instance, the absence of differences in 
BTM and/or sclerostin at baseline. Second, it lacks direct evaluation of bone 
histology and metabolism. A bone biopsy before and after GC treatment would have 
been desirable to correlate the findings from serum with actual effects on bone 
remodelling, however, it was deemed as not being ethical. Long-term observations 
of patients (e.g. after 6-12 months of GC therapy and in stable remission) would 
have been of interest to better investigate the direct effects of GCs in PMR on bone 
metabolism, however, since all patients started anti-resorptive therapy after 1 month 
of GC therapy (which is in accordance with national guidelines), an unbiased 
assessment would not have been possible.  
In conclusion, this study  for the first time showed that, in treatment-naïve PMR, 
systemic inflammation is associated with a dysregulation of the Wnt system 
(especially due to the increase in Dkk-1), similarly to what has been observed in 
RA. Treatment with GC, currently the mainstay therapy for PMR, is associated with 
suppression of Dkk-1 and sclerostin with a consensual reduction in bone resorption. 
Nevertheless, CG still show some undesired effects on bone metabolism, namely 




In PMR a different anti-inflammatory approach such as treatment with IL-6 
blockers could enable us to control disease and inflammation limiting the negative 
consequences of GC on bone health. 
 
Study n° 3 - Diffuse idiopathic skeletal hyperostosis (DISH) in type 2 diabetes: 
a new imaging possibility and a new biomarker 
The main and novel findings of this study including post-menopausal women with 
non-insulin-treated T2DM are as follows: (1) the prevalence of DISH is high 
(affecting up to nearly 21% of these women); and (2) serum sclerostin levels are 
inversely associated with the presence of DISH, even after adjustment for age and 
years in menopause. 
We identified women affected by DISH with VFA, a radiographic technique 
derived from DXA for the detection of vertebral fractures (93,94). We chose the 
VFA since the radiation dose is considerably lower (42 μSv) than conventional 
radiography (500 μSv) (95); furthermore, DXA’s X-ray beams are parallel to the 
endplates as compared to the fan-shaped beans of conventional radiography, 
eliminating the geometric distortion and image amplification that affect 
conventional radiography (96). Indeed, with DXA we can obtain a single image of 
the entire spine, whereas with conventional radiography we would have need 
multiple exposures to evaluate the whole spine. It is important to highlight that 
T2DM is a known risk factor for DISH (97–99). In our study, importantly, the 
prevalence of DISH (20%), assessed with VFA, was substantially in line with a 
previously published report (98), confirming the validity of VFA in diagnosing 
DISH. We also investigated the association between DISH and a wide variety of 
biomarkers in a cohort of post-menopausal women with T2DM and confirmed the 
presence of a dysregulation in the Wnt pathway (as reflected by lower serum 
sclerostin levels) in the subgroup of those with DISH. 
Dysregulation of the canonical Wnt pathway in rheumatic diseases and bone 
metabolic diseases has been increasingly studied in recent years and its 
dysregulation has been shown to be involved in multiple diseases (42,55,100–103). 
However, the currently available data on Wnt pathway modulators in DISH are 
scarce. Niu et al. observed decreased serum Dkk-1 levels and increased sclerostin 
levels in a small sample of DISH patients (n=8) when compared to healthy controls; 
however, no information on presence of T2DM was available. Senolt et al. also 
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confirmed the presence of lower levels of Dkk-1 in 37 patients with DISH than in 
age- and sex-matched controls (104), but no data on serum sclerostin levels were 
available. Our result on sclerostin serum levels was even more evident after 
adjustment for two potentially confounding factors, such as age and years in 
menopause. We can speculate that the decreased expression of sclerostin can induce 
a pro-osteogenic environment and, therefore, might explain the pathologic bone 
formation and soft-tissue ossifications seen in DISH patients better than PINP and 
PTH. This hypothesis should be further tested in future studies including a healthy 
control group in order to compare the Wnt profile of T2DM patients to that of the 
nondiabetic healthy population according to the presence or absence of DISH. We 
investigated other serum biomarkers, including bone turnover markers and RANKL 
as well as markers of insulin resistance, but we failed to observe any significant 
difference in these biomarkers between postmenopausal T2DM women with and 
without DISH. In addition, we did not find any difference in the prevalence of other 
important comorbid conditions betwTeen the two patient groups. Therefore, aside 
from Wnt dysregulation, the possible presence of other “drivers” of pathologic bone 
formation in DISH remains currently unclear.  
The higher-than-average BMD values expressed as Z-scores (largely higher than 
zero in our cohort of patients) at all sites, together with the remarkable prevalence 
of vertebral fractures, are expected finding in our cohort. Indeed, it is well known 
that T2DM and overweight/obesity are strongly associated with increased bone 
fragility despite higher BMDs (105,106). However, we emphasize the fact that, 
especially at lumbar spine, we observed high BMD levels in both DISH and no-
DISH patient groups, therefore confirming the presence of BMD values ad lumbar 
spine (as measured by DXA) higher than expected also in the patients without 
DISH. 
Interestingly, very recently, a retrospective study on the incidence of cardiovascular 
disease on subjects with DISH has documented a significantly higher risk for 
myocardial infarction after adjustment for multiple confounders (OR 6.03, 95%CI 
1.06-34.2) (107). This, indeed, may support the rational for screening in a high-risk 
population for both cardiovascular disease and DISH itself. 
Our study has some important limitations that should be mentioned. First, the cross-
sectional design of the study limits our ability to establish causality and temporality 
of the observed associations. Moreover, multiple biomarkers were tested and this 
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needs to be considered, however, given its exploratory nature, adjustment for 
multiplicity was not made in order to avoid a reduction in sensitivity. Second, given 
that we included only Caucasian female outpatients with non-insulin-treated 
T2DM, our findings may not necessarily be generalizable to other T2DM 
populations of different ethnicity. Third, the diagnosis of DISH was made upon 
VFA, an imaging technique that has not been yet validated for this purpose. This 
approach has been used before in the evaluation of radiographic damage in patients 
affected by ankylosing spondylitis with good performance results when compared 
with X-rays [33]. We found a good inter-observer agreement the VFA evaluation 
and when X-rays were available for the DISH patients (10 subjects), in all cases the 
diagnosis was confirmed. Clearly, this cannot be considered a definitive evidence 
in the absence of a proper radiographic comparative study. In our opinion, VFA 
evaluation might be able to identify the disease in the most expressed forms and 
therefore the main expected limitation might be a lower sensitivity of VFA. We 
think that this technique should be further studied for screening purposes for the 
identification of DISH in at-risk subjects (i.e., dysmetabolic individuals) and 
compared to X-rays to establish specificity and sensibility data. Fourth, we should 
consider that prevalence of DISH has been reported to be higher in men than in 
women (108,109). Our study showed a high prevalence of DISH in diabetic women, 
but it is likely that in diabetic men the prevalence of the disease might be even 
higher; therefore it is reasonable to candidate the quick and low-dose VFA as a 
screening tool in these higher risk cohorts. Lastly, as already mentioned, is the 
absence of a healthy control group.  
Notwithstanding these limitations, the main strengths of our study were the 
relatively large size of the sample, the wide number of bone turnover biomarkers 
analysed and those with important comorbid conditions (e.g., advanced kidney 
disease, cirrhosis or active cancer) or taking medications known to interfere with 
bone metabolism. We believe that including patients with these conditions might 









Over the course of my PhD program I investigated the Wnt pathway in the 
development of the bone damage. In previous studies, we demonstrated two 
fundamental concepts: 
a) In RA, a disease characterized by focal and systemic bone loss, the 
dysregulation of the Wnt system is due to an increased production of its 
inhibitors Dkk1- and sclerostin 
b) In AS and PsA, that are also characterised by pathologic bone formation, 
the dysregulation of the Wnt system is associated with decrease levels of 
Wnt inhibitors. We hypothesized that Dkk-1 and/or sclerostin depression 
could be one risk factor for a pathologic osteogenic environment. 
Base on these premises, we further expanded our knowledge and provided answers 
to important questions. The key points are 
1) In RA, Wnt inhibitors are induced by pro-inflammatory conditions. 
Treatment with potent anti-inflammatory drugs deeply affects the pathway. 
In the specific, TNFi act very rapidly and decrease (normalize) Dkk-1 and 
sclerostin serum levels; these changes are also associated with positive 
comebacks on BTMs (increase in PINP, reduction in CTX-I). GCs have a 
mixed effect: they reduce the levels of Wnt inhibitors, but also exert a 
negative direct effect on bone formation. Indeed, they are associated with 
mixed effects on bone health (i.e. decrease in Dkk-1, but also in PINP, a 
marker of bone formation). Finally, the acute effect of tocilizumab (anti-
IL6R) was fount to be not significant, at least within the 4 weeks timeframe. 
2) PMR is a different disease from RA, albeit it shares a strong and 
dysregulated inflammatory response. The effects of treatment with GCs in 
PMR is, once again, mixed: on one hand we found a decrease in the Dkk-1 
and sclerostin serum levels, associated with a decrease in CTX-I (a marker 
of bone resorption). However, similarly to what happened in RA, also a 
decrease in PINP was observed, arguably due to the same negative and 
direct effect of GCs on the osteoblasts’ activity. 
3) The finding of decreased Wnt inhibitors' levels might indeed be a common 
trait of pathologic conditions associated with inappropriate bone formation. 
In DISH, a rheumatic disease characterized by flowing ossification at 
multiple vertebral sites but not associated with any inflammatory 
35 
 
component, sclerostin was observed to be the sole biomarker distinguishing 
the affected subjects from controls. 
 
A final overview and future directions 
The Wnt pathway is one of the cornerstones of osteogenesis. There is now an 
overwhelming body of evidence pointing to its dysregulation on rheumatic diseases. 
The notion of excessively elevated expression of Wnt inhibitors in RA is now 
established. We also demonstrated that the link between the production of pro-
inflammatory cytokines and this increase, already shown in laboratory experiments, 
is also seen in live subjects. Treatment with anti-inflammatory drugs can rapidly 
interfere. On the other hand, the data on the Wnt dysregulation on SpA are still 
scarce and less solid. Our working hypothesis is, along with the presence of pro-
inflammatory cytokines and the role of IL-17, the presence of a systemic 
environment favoring pathologic bone formation at specific sites. Our data suggest 
that this observation might also be a common trait in conditions not characterized 
by significant systemic inflammation like DISH. 
At this point, we will aim our future investigations at: 
1) Demonstrating the clinical utility of Dkk-1 and sclerostin as predictive 
biomarkers for bone damage in patients with RA 
2) Further strengthening the evidence of the Wnt pathway's dysregulation in 
conditions such as AS, though the analysis of the relationship between 
different treatments (i.e. anti-IL17 vs TNFi), structural damage progression 
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